Therapeutic Areas

Psychiatric and neurologic trials from first-in-human (FIH) through Phase 1b and proof-of-concept (PoC) studies, across multiple indications and the full range of central nervous system (CNS) assessments. Backed by 25+ years of early phase experience and a neuroscience team that has contributed to numerous successful New Drug Applications.

50+ first-in-human (FIH) through Phase 1b and proof-of-concept (PoC) studies in substance use and dependence populations, supported by a DEA-registered clinical pharmacology unit purpose-built for controlled substances.

Providing specialized clinical research services for Tobacco Harm Reduction (THR) programs, supporting sponsors from early protocol development through regulatory submission. Leveraging experienced study teams, a dedicated clinical pharmacology unit and regulatory expertise to help generate the data required for PMTAs and other regulatory pathways.

Led by William Lavery, MD, PhD, our team supports a wide range of allergy and immunology programs, from first-in-human (FIH) through Phase 1b and proof-of-concept (PoC) studies.

We have strong recruiting capabilities for participants who are overweight, obese or who have associated cardiometabolic disorders. Our team has conducted dozens of cardiometabolic studies in healthy volunteer and patient populations. Experience spanning SAD/MAD studies, Phase Ib and proof-of-concept (PoC) trials.

Our team supports a wide range of pain programs, from first-in-human (FIH) through Phase 1b and proof-of-concept (PoC) studies. Our pain research is built around experienced ratings teams, disciplined data collection and consistent execution.

Led by our Medical Director and Principal Investigator Steven Hull, MD, a pulmonologist with 35 years of experience, our team has conducted a wide range of respiratory studies in health volunteers and patient populations from first-in-human (FIH) through Phase Ib and proof of concept (PoC).

Dermatology trials from first-in-human (FIH) through Phase 1b and proof-of-concept (PoC) studies, across a range of dermatologic indications and clinical assessments. Focused dermatology expertise and integrated CRO execution support efficient, well-coordinated study delivery from start-up through completion.

We support a wide range of infectious disease and vaccine programs, from first-in-human (FIH) through Phase 1b and proof-of-concept (PoC) studies with experience in both healthy volunteer and patient populations.